Alvotech
ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arth… read more
Healthcare
Drug Manufacturers—Specialty & Generic
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.21
Price+2.05%
$0.17
1Y
Price
Market Cap
$2.476b
Mid
Price/Earnings 3y Avg5y Avg
35.7x
Premium
Premium
Financials Overview
Key metrics over the past few years-528.5%
EBITDA Margin-1759.7%
Net Profit Margin-643.7%
Free Cash Flow MarginRevenue
$560.096m
-3.8%
1y CAGR+44.1%
3y CAGR+21.8%
5y CAGREarnings
$63.358m
+10.4%
1y CAGR-134.3%
3y CAGR-90.7%
5y CAGREPS
$0.19
+24.3%
1y CAGR+16.9%
3y CAGR+22.8%
5y CAGRBook Value
-$173.328m
$1.393b
Assets$1.566b
Liabilities$1.268b
DebtDebt to Assets
91.0%
-3.6x
Debt to EBITDAFree Cash Flow
-$139.824m
+5.6%
1y CAGR-9.4%
3y CAGR-59.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company